

Supplemental Figure 1. PRISMA Flow Diagram of Study Identification, Screening, and Selection

^a Category *n*'s do not sum to total *N* because articles could be excluded for multiple reasons.

		Domain-Specific		Global SED					
	Prevalence				Prevalence				
Study Type	(%)	95% CI	k	N	(%)	95% CI	k	N	
US National Sample	10.75	10.22 - 11.29	2	21,907	6.75	5.91 - 7.58	3	35,226	
Regional Sample	9.84	7.98 – 11.70	8	10,108	5.76	4.98 - 6.55	5	3,713	
Taxonomic DSM Diagnoses	10.00	8.33 - 11.65	9	13,150	5.96	5.21 - 6.71	6	10,196	
Quantitative Rating Scale	10.70	10.14 - 11.26	1	18,865	6.62	5.74 - 7.51	2	28,743	
12-month Timeframe	11.26	10.38 - 12.15	3	7,480	6.99	4.84 - 9.14	2	6,746	
< 12-month Timeframe	9.46	7.60 - 11.31	7	24,535	6.29	5.67 - 6.91	6	32,193	
Data Collected before 1992	10.09	7.66 - 12.52	6	4,918	5.55	4.68 - 6.41	4	2,698	
Data Collected after 1992	10.26	8.68 - 11.74	4	27,097	6.73	6.03 - 7.43	4	36,241	
Total	10.06	8.60 - 11.51	10	32,015	6.36	5.78 - 6.93	8	38,939	

Supplemental Table 1. Meta-Analyses of Serious Emotional Disturbance (SED) Prevalence by Study Type and Level of Impairment

Note: k = number of studies included in the meta-analysis, N = number of youth included in the meta-analysis.

Study Set								Ν	k
Domain-Specific SED									
US National Sample Regional Sample Taxonomic DSM Diagnoses Quantitative Rating Scale 12-month Timeframe < 12-month Timeframe Data Collected before 1992 Data Collected after 1992					 			21,907 10,108 13,150 18,865 7,480 24,535 4,918 27,097	2 9 1 3 7 6 4
Domain-Specific SED Total			F					32,015	10
Global SED									
US National Sample Regional Sample Taxonomic DSM Diagnoses Quantitative Rating Scale 12-month Timeframe < 12-month Timeframe Data Collected before 1992 Data Collected after 1992	,			-				35,226 3,713 10,196 28,743 6,746 32,193 2,698 36,241	35622644
Global SED Total		⊦-■	4					38,939	8
	Γ	I	I		I				
	4	6	8	10	12	14	16		
			Prev	alence	e (%)				

Supplemental Figure 2. Meta-Analytic Prevalence Estimates of Serious Emotional Disturbance (SED) by Study Type and Level of Impairment.

Note: N = number of youth included in meta-analytic estimate; k = number of studies included in meta-analytic estimate.

Study	Ν								Age	Range
NY	764		 -1						91	to 18
Oregon	1710		⊢-■	-					14	to 18
Pitt	263			— —				-	12	to 18
MECA	1285			—	-	-			91	to 17
Boston	386				— —	-			17	to 18
Chicago	510		·	■;					2	to 5
GSMS	1015	F	-						91	to 16
Houston	4175								11	to 17
NHANES	3042			·	-	-			81	to 15
MEPS	18865			⊢∎	-				6	to 17
			-	•						
			1							
		4 6	8	10	12	14	16	18	20	
	Prevalence (%), Domain-Specific SED									

Supplemental Figure 3. Domain-Specific SED Prevalence Estimates Ordered by Year of Data Collection.

Supplemental Figure 4. Global SED Prevalence Estimates Ordered by Year of Data Collection.

Study	Ν		Age Range				
NY	764	⊢	9 to 18				
Pitt	263	·	12 to 18				
MECA	1285	┝──╋──┤	9 to 17				
Boston	386	⊢₽	17 to 18				
GSMS	1015	⊢	9 to 16				
NHIS	9878	⊢∎⊣	4 to 17				
NCS-A	6483	⊦	13 to 17				
MEPS	18865	⊨∎⊣	6 to 17				
		•					
	Г						
	2	4 6 8 10	12				
Prevalence (%), Global SED							